Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST 1481 second-line treatment in advanced or metastatic pancreatic cancer
ChiCTR2100042993Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gimatecan in pancreatic cancer (PC) (2 arms), sponsored by Renji Hospital. Primary endpoints: progression-free survival and disease control rate. Started Feb 2021; status: recruiting.
02
Drugs
gimatecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2100042993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042993.